Organigram Global Inc.

NASDAQ:OGI

Drug Manufacturers - Specialty & Generic

Healthcare
$0.68 -1.74%

-$0.02 today

Market cap
$95.40M
Beta
1.84
P/E (TTM)
-7.2
EPS (TTM)
-$0.19
52W Low $0.97High $2.24

Volume 0.62M

Average 0.67M

OGI Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Organigram Global Inc.NASDAQ: OGI

Research & Development · Q2 FY2026 · quarter ended Mar 2026

Research & development dips below year-ago levels

Q2 FY2026 research & development of CA$2.03M fell 23.9% year over year, behind the +9.4% change in trailing-twelve-month research & development. Sequentially, it fell 2.8% from the prior quarter.

Context

  • Research & development amounted to 5.9% of revenue in FY2025, down 1.1 pp from a year earlier.
  • Research & development increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -23.9% toward the trailing-twelve-month pace of +9.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
CA$2.03M-2.8% QoQ
Last fiscal yearSep 2025
CA$10.95M-2.3% YoY
LTMMar 2026
CA$10.02M+9.4% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-23.9%——
1 year-2.3%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Research & Development history

CAD · from the income statement

Latest · FY2025
10.95M CAD
Year-over-year change
-2.3%
4-year CAGR
+33.5%

Research & Development vs competitors

How OGI compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +9.4% is the 5th highest of 8, against a peer median of +25.5%.
  • Research & development amounts to 3.7% of revenue for OGI, versus a peer median of 5.6%.
OGI Competitors
Research & Development for OGI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IVAInventiva S.A.FY2025€83.61M EUR-8.0%+11.4%1865.0%
RNACCartesian Therapeutics, Inc.LTM Mar 2026$62.82M USD+25.5%-7.1%3539.3%
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026$60.48M USD+28.2%+38.4%184.8%
OGIOrganigram Global Inc.LTM Mar 2026CA$10.02M CAD+9.4%—3.7%
LFCRLifecore Biomedical, Inc.LTM Mar 2026$7.58M USD—+1.8%5.6%
ACBAurora Cannabis Inc.LTM Mar 2026CA$4.98M CAD+35.4%+1.4%1.6%
HSDTSolana CompanyLTM Mar 2026$2.57M USD-32.8%-6.3%26.8%
ELMDElectromed, Inc.LTM Mar 2026$1.29M USD+48.0%-9.8%1.8%
DERMJourney Medical CorporationLTM Mar 2026$441K USD-78.1%-64.7%0.7%
INFUInfuSystem Holdings, Inc.LTM Mar 2026$0 USD——0.0%
Peer median (excluding OGI) —+25.5%-2.4%5.6%

Competitors are the stored peer set for OGI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CAD
Metric
FY2021
Aug 2021
FY2022
Aug 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
Revenue79.16M145.81M149.21M159.84M186.09M
Cost of Revenue107.56M114.24M114.13M112.32M179.26M
Gross Profit(28.4M)31.57M35.07M47.52M6.83M
Gross Margin-35.9%21.7%23.5%29.7%3.7%
Research & Development3.45M5.96M12.19M11.2M10.95M
Selling, General & Admin46.47M59.21M71.68M68.14M86.88M
Operating Expenses63.42M74.72M271.48M83.2M70.24M
Depreciation & Amortization31.03M24.91M23.43M12.08M12.91M
EBITDA(96.71M)10.97M(25.37M)(23.59M)(14.76M)
EBITDA Margin-122.2%7.5%-17.0%-14.8%-7.9%
Operating Income(91.82M)(43.15M)(242.74M)(35.67M)(63.41M)
Operating Margin-116.0%-29.6%-162.7%-22.3%-34.1%
Interest Income003.69M0825.7K
Interest Expense2.96M429K277.85K00
Other Income / Expenses(38.88M)28.78M(184.21M)(9.77M)35.74M
Income Before Tax(130.7M)(14.37M)(233M)(45.44M)(27.66M)
Pre-Tax Margin-165.1%-9.9%-156.2%-28.4%-14.9%
Income Tax Expense0(88K)(3.52M)0(9.89M)
Net Income(130.7M)(14.28M)(229.48M)(45.44M)(17.78M)
Net Margin-165.1%-9.8%-153.8%-28.4%-9.6%
EPS (Basic)(2.04)(0.18)(2.82)(0.48)(0.14)
EPS (Diluted)(2.04)(0.18)(2.82)(0.48)(0.14)
Weighted Avg Shares64.03M80.01M81.29M95.29M127.67M
Weighted Avg Shares (Diluted)64.03M85.3M81.29M95.29M127.67M

Organigram Global Inc.

NASDAQ:OGI

Intrinsic Alpha fair value

Locked

Current Price

$0.68

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.